Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha
- PMID: 21051638
- DOI: 10.1126/science.1195300
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha
Abstract
The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was first identified in human cancers expresses fibroblast activation protein-α (FAP). We created a transgenic mouse in which FAP-expressing cells can be ablated. Depletion of FAP-expressing cells, which made up only 2% of all tumor cells in established Lewis lung carcinomas, caused rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors by a process involving interferon-γ and tumor necrosis factor-α. Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma also permitted immunological control of growth. Therefore, FAP-expressing cells are a nonredundant, immune-suppressive component of the tumor microenvironment.
Comment in
-
Cancer. Awakening immunity.Science. 2010 Nov 5;330(6005):761-2. doi: 10.1126/science.1198345. Science. 2010. PMID: 21051618 No abstract available.
Similar articles
-
Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.Cancer Immunol Res. 2014 Feb;2(2):121-6. doi: 10.1158/2326-6066.CIR-13-0150. Epub 2013 Nov 18. Cancer Immunol Res. 2014. PMID: 24778275 Free PMC article.
-
The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.Cancer Immunol Res. 2014 Mar;2(3):187-93. doi: 10.1158/2326-6066.CIR-14-0002. Cancer Immunol Res. 2014. PMID: 24778314
-
A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.Sci Rep. 2015 Sep 23;5:14421. doi: 10.1038/srep14421. Sci Rep. 2015. PMID: 26394925 Free PMC article.
-
The application of the fibroblast activation protein α-targeted immunotherapy strategy.Oncotarget. 2016 May 31;7(22):33472-82. doi: 10.18632/oncotarget.8098. Oncotarget. 2016. PMID: 26985769 Free PMC article. Review.
-
Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies.Int Rev Cell Mol Biol. 2012;297:83-116. doi: 10.1016/B978-0-12-394308-8.00003-0. Int Rev Cell Mol Biol. 2012. PMID: 22608558 Review.
Cited by
-
Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial.Breast Cancer Res Treat. 2021 May;187(1):45-55. doi: 10.1007/s10549-021-06136-4. Epub 2021 Mar 4. Breast Cancer Res Treat. 2021. PMID: 33661437 Free PMC article. Clinical Trial.
-
Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.PLoS One. 2013;8(3):e58860. doi: 10.1371/journal.pone.0058860. Epub 2013 Mar 12. PLoS One. 2013. PMID: 23554941 Free PMC article.
-
Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.Int J Mol Sci. 2021 May 17;22(10):5283. doi: 10.3390/ijms22105283. Int J Mol Sci. 2021. PMID: 34067929 Free PMC article. Review.
-
Microenvironment M1/M2 macrophages and tumoral progression vary within C57BL/6 mice from same substrain in prostate cancer model.Sci Rep. 2024 Jul 2;14(1):15112. doi: 10.1038/s41598-024-65960-y. Sci Rep. 2024. PMID: 38956203 Free PMC article.
-
The secret ally: immunostimulation by anticancer drugs.Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33. doi: 10.1038/nrd3626. Nat Rev Drug Discov. 2012. PMID: 22301798 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous